King of Prussia’s SEED Therapeutics is tackling one of medicine’s toughest challenges, writes Holly Quinn for Technical.ly.
The biotech startup is treating diseases driven by proteins that current drugs can’t reach. The company is pioneering “molecular glues,” tiny drug molecules that fasten harmful proteins to a cell’s natural disposal system. Once tagged, the proteins are broken down. This is a breakthrough approach that could open new doors for cancer treatments and other conditions long considered out of reach.
SEED is already advancing to the clinic, led by CEO Lan Huang and President James Tonra. The FDA recently approved its first trial for Ewing sarcoma, a rare cancer that mainly affects young people. The program has earned “rare pediatric” and “orphan drug” status, giving the company regulatory advantages and potential incentives.
SEED has quickly established itself as a player in Montco’s growing biotech corridor. After moving into the former GSK R&D hub in 2022, it exceeded hiring goals within weeks. Partnerships with Eli Lilly and Eisai, along with recognition as a finalist for the 2025 Prix Galien USA “Best Startup” Award, reinforce its momentum.
“The goal is to have patients as our North Star,” Huang said. “To give them new hope, and restore their health.”
To learn more about SEED Therapeutics and their groundbreaking therapy, visit Technical.ly.
Editor’s Note: This post was originally published on MONTCO.Today in September 2025.
